Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All Groups:~  * Must not have a fever of ≥100.4° F on the day of vaccination~ * Any underlying chronic illness must be in stable condition~ * History of varicella or residence in a VZV-endemic area for ≥30 years~* Group 1:~  * 70 years of age or older~ * Took part in the Shingles Prevention Study (SPS) (V211-004, NCT00007501) and received a single dose of Zoster Vaccine, Live ≥10 years prior to enrollment in this study~* Group 2:~  * 70 years of age or older~* Group 3:~  * 60 to 69 years of age~* Group 4:~  * 50 to 59 years of age~Exclusion Criteria:~* All Groups:~  * History of hypersensitivity reaction to any vaccine component or an anaphylactic/anaphylactoid reaction to neomycin~ * Prior history of herpes zoster~ * Pregnant or breast-feeding, or expecting to conceive within the duration of the study~ * Has been treated with immunoglobulin or any blood products, other than autologous (self-donated) blood transfusion, in the 5 months prior to vaccination~ * Received any other vaccine within 4 weeks prevaccination~ * On immunosuppressive therapy~ * Has known or suspected immune dysfunction~ * Is taking any non-topical antiviral therapy with activity against herpesviruses, including, but not limited to acyclovir, famciclovir, valacyclovir, and ganciclovir.~* Groups 2, 3, and 4:~  * Has previously received any varicella or zoster vaccine

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1: Booster Dose Participants ≥70 years of age (Type: EXPERIMENTAL): Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study V211-004 NCT00007501)
- Group 2: First Dose Participants ≥70 years of age (Type: EXPERIMENTAL): Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age
- Group 3: First Dose Participants ≥60 and <70 years of age (Type: EXPERIMENTAL): Herpes zoster history-negative participants ≥60 and \<70 years of age who have never received Zoster Vaccine, Live
- Group 4: First Dose Participants ≥50 and <60 years of age (Type: EXPERIMENTAL): Herpes zoster history-negative participants ≥50 and \<60 years of age who have never received Zoster Vaccine, Live

Based on this trial design, predict the completion outcome and termination type (if applicable).